Xcout Intel
Scout Bio, Inc.
Scout Bio, Inc. is a veterinary biotechnology company specializing in animal health and advanced gene therapy treatments currently being evaluated in clinical trials.
Subscribe to see Scout Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Scout Bio, Inc. at a glance
Scout Bio, Inc. is a biopharma company headquartered in United States. Its most recent funding round raised $4.8M in October 2021. Xcout tracks 11 named people at Scout Bio, Inc., including Dr Sébastien Huron (DEPUTY CEO).
Scout Bio, Inc. leadership
- Dr Sébastien HuronDEPUTY CEO
- Christophe BailetEXECUTIVE VICE-PRESIDENT, CHIEF FINANCIAL OFFICER
- Dr Marc PrikazskyEXECUTIVE CHAIRMAN
- Jean-Marcel CietEXECUTIVE VICE PRESIDENT GLOBAL COMPANION ANIMALS
- David DerainEXECUTIVE VICE-PRESIDENT, HUMAN RESOURCES
- Dr Andras BolcskeiEXECUTIVE VICE-PRESIDENT, GLOBAL SALES OPERATIONS
5 more named people on record for Scout Bio, Inc., with roles, board committees and tenure — see the full roster →
Scout Bio, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $4.8M | — | |
| Series B | $33M | 12 named | |
| SEC Form D filing | $20M | — | |
| Series B | $20M | 11 named | |
| SEC Form D filing | $9.3M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Scout Bio, Inc. competitors
A few of Scout Bio, Inc.'s closest competitors — see the full list of competitors and alternatives →
VectorY Therapeutics is a fully integrated gene therapy company founded in August 2020 and based in Amsterdam, Netherlands. The company is focused on developing novel gene therapies, including clinical trials for conditions like amyotrophic lateral sclerosis (ALS).
PulseSight Therapeutics is an ophthalmology biotechnology company headquartered in Paris, France, specializing in the development of disruptive non-viral vectorized gene therapies.
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Orbital Therapeutics is a biotechnology company developing RNA medicines, with a focus on engineered circular RNA and delivery technologies. Its programs are intended to address diseases that may benefit from durable, programmable protein expression, serving patients and healthcare providers through potential therapeutic products.
Renibus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Southlake, Texas, dedicated to transforming outcomes in specialty therapeutics and disease treatments.
BobcatBio, Inc. is a clinical-stage biotechnology company founded in 2020 and headquartered in Hummelstown, Pennsylvania. The company focuses on developing macrophage-based cell therapies and cancer-specific immunotherapies, including its lead cellular therapy candidate RB-1355, for the treatment of solid tumors.
Get Scout Bio, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Scout Bio, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access